Pharmacotherapy of schizophrenia;A szkizofrénia gyógyszeres kezelése

Neuropsychopharmacologia Hungarica

Volumn 13, Issue 4, 2011, Pages 239-247

  Gábor, Kovács ^a  

^a Honvédkórház   (Hungary)

Author keywords

Antipsychotics; Pharmacotherapy; Schizophrenia

Indexed keywords

ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ANXIOLYTIC AGENT; NEUROLEPTIC AGENT;

ANXIETY DISORDER; BINDING AFFINITY; CLINICAL DECISION MAKING; COMORBIDITY; DEPRESSION; DRUG ABSORPTION; DRUG BINDING; EXTRAPYRAMIDAL SYMPTOM; HUMAN; LONG TERM CARE; NEGATIVE SYNDROME; PHARMACODYNAMICS; POSITIVE SYNDROME; PSYCHOPHARMACOTHERAPY; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; REVIEW; SCHIZOPHRENIA; TREATMENT RESPONSE;

ACUTE DISEASE; ANTIPSYCHOTIC AGENTS; DRUG THERAPY, COMBINATION; HUMANS; SCHIZOPHRENIA;

EID: 84858241127     PISSN: 14198711     EISSN: None     Source Type: Journal    
DOI: 10.5706/nph201112008     Document Type: Review

References (23)

1. Bishop, J. R., Chae, S. (2010) Should you order genetic testing to identify how patients metabolize antipsychotics? Curr Psychiatr, 9:32-35.
2. Boter, H., Peuskens, J., Libiger, J., Fleischhacker, W. W., Davidson, M., Galderisi, S., Kahn, R. S. (2009) Effectiveness of antipsychotics in first-episode schizophrenia and schizophreniform disorder on response and remission: an open randomized clinical trial (EUFEST). Schizophr Res, 115:97-103.
3. Correll, C. U. (2010) From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur Psychiatry, 25 Suppl 2:S12-21.
4. Fleeman, N., Dundar, Y., Dickson, R., Jorgensen, A., Pushpakom, S., McLeod, C., Pirmohamed, M., Walley, T. (2011) Cytochrome P450 testing for prescribing antipsychotics in adults with schizophrenia: systematic review and meta-analyses. Pharmacogenomics J, 11:1-14.
5. Fumagalli, F., Frasca, A., Racagni, G., Riva, M. A. (2009) Cognitive effects of second-generation antipsychotics: current insights into neurochemical mechanisms. CNS Drugs, 23:603-14.
6. Gazdag, G., Ungvari, G. S. (2011) Non-pharmacological biological therapies in schizophrenia. Neuropsychopharmacol Hung, 13:233-238.
7. Goodwin, G., Fleischhacker, W., Arango, C., Baumann, P., Davidson, M., de Hert, M., Falkai, P., Kapur, S., Leucht, S., Licht, R., Naber, D., O'Keane, V., Papakostas, G., Vieta, E., Zohar, J. (2009) Advantages and disadvantages of combination treatment with antipsychotics ECNP Consensus Meeting, March 2008, Nice. Eur Neuropsychopharmacol, 19:520-32.
8. Jindal, R. D., Keshavan, M. S. (2008) Classifying antipsychotic agents: need for new terminology. CNS Drugs, 22:1047-59.
9. Kalman, J., Kalman, S. (2011) The conceptual re-evalutation of therapeutic success in schizophrenia. Neuropsychopharmacol Hung, 13:249-256.
10. Kane, J. M., Correll, C. U. (2010) Pharmacologic treatment of schizophrenia. Dialogues Clin Neurosci, 12:345-57.
11. Kapur, S., Mizrahi, R., Li, M. (2005) From dopamine to salience to psychosis--linking biology, pharmacology and phenomenology of psychosis. Schizophr Res, 79:59-68.
12. Keshavan, M. S., Tandon, R., Boutros, N. N., Nasrallah, H. A. (2008) Schizophrenia, "just the facts": what we know in 2008 Part 3: neurobiology. Schizophr Res, 106:89-107.
13. Kinon, B. J., Chen, L., Ascher-Svanum, H., Stauffer, V. L., Kollack-Walker, S., Zhou, W., Kapur, S., Kane, J. M. (2010) Early response to antipsychotic drug therapy as a clinical marker of subsequent response in the treatment of schizophrenia. Neuropsychopharmacology, 35:581-90.
14. Leucht, S., Corves, C., Arbter, D., Engel, R. R., Li, C., Davis, J. M. (2009) Second-generation versus first-generation antipsychotic drugs for schizophrenia: a meta-analysis. Lancet, 373:31-41.
15. Linnet, K., Ejsing, T. B. (2008) A review on the impact of Pglycoprotein on the penetration of drugs into the brain. Focus on psychotropic drugs. Eur Neuropsychopharmacol, 18:157-69.
16. Martins, P. J., Haas, M., Obici, S. (2010) Central nervous system delivery of the antipsychotic olanzapine induces hepatic insulin resistance. Diabetes, 59:2418-25.
17. Miller, D. D., McEvoy, J. P., Davis, S. M., Caroff, S. N., Saltz, B. L., Chakos, M. H., Swartz, M. S., Keefe, R. S., Rosenheck, R. A., Stroup, T. S., Lieberman, J. A. (2005) Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr Res, 80:33-43.
18. Möller, H. J. (2010) Long-term pharmacotherapy of schizophrenic patients: Achievements, unsolved needs and future perspectives with special focus on long-acting injectable second generation antipsychotics. Archives of Psychiatry and Psychotherapy 4:13-21.
19. Naber, D., Lambert, M. (2009) The CATIE and CUtLASS studies in schizophrenia: results and implications for clinicians. CNS Drugs, 23:649-59.
20. Pani, L., Pira, L., Marchese, G. (2007) Antipsychotic efficacy: relationship to optimal D2-receptor occupancy. Eur Psychiatry, 22:267-75.
21. Rethelyi, J. (2011) From Bleuler to DSM-V: Diagnosing schizophrenia. Neuropsychopharmacol Hung, 13:193-203.
22. Tsutsumi, C., Uchida, H., Suzuki, T., Watanabe, K., Takeuchi, H., Nakajima, S., Kimura, Y., Tsutsumi, Y., Ishii, K., Imasaka, Y., Kapur, S. (2011) The evolution of antipsychotic switch and polypharmacy in natural practice--a longitudinal perspective. Schizophr Res, 130:40-6.
23. Weiser, M. (2011) Early intervention for schizophrenia: the risk-benefit ratio of antipsychotic treatment in the prodromal phase. Am J Psychiatry, 168:761-3.